Editor's note: The summer strips are green and the vermilion is bright and fresh. Time flies, Langmu ® has been on the market for 8 years, bringing many benefits to patients. "Clear Love, Only for China" Eight Years of Anti-VEGF Warfare and Innovation Light - Langmu ® 8th Anniversary of Listing, On June 26, 2022, in Beijing, Chengdu, Hangzhou, Guangzhou, Shanghai 5 conference venues, online and offline synchronously opened 2 academic conferences, gathered hundreds of participants, celebrated Langmu's ®8th birthday, congratulated The approval of retinal vein obstruction (RVO) indications, and the approval of Gonghe prefill dosage form.
In 2014, the listing of Langmu ® broke the monopoly of foreign-funded drugs in the field of ophthalmic anti-VEGF in China. In the past 8 years, Langmu ® has been full of wind and rain and fruitful results. As a representative of China's innovative biological drugs, the anniversary celebration of Langmu ® is not only an important moment for Kang Hong, but also a common event for the Chinese ophthalmology community. At this event, Kanghong Pharmaceutical joined hands with nearly 2,000 top ophthalmologists and ophthalmologists at home and abroad, online and offline synchronous live broadcast, 5 linkages, opened the academic ceremony in the field of ophthalmology, the forum focused on scientific and technological innovation and transformation, cutting-edge therapy progress, precision medicine development, jointly explored the new progress and new direction of fundus disease diagnosis and treatment, reviewed the anti-VEGF road of Langmu ® in the past 8 years, and jointly looked forward to a better tomorrow for Langmu ®.
Before the meeting, just when Langmu ® (Compaxipu Eye Injection) was approved as the fourth major indication - the treatment of visual impairment caused by macular edema secondary to retinal vein obstruction (RVO), the conference held a RVO indication listing ceremony, since then, RVO treatment has entered a new era of dual-target therapy, ushering in a triple upgrade of anti-VEGF drug therapy: target upgrade, speed upgrade, efficacy upgrade, bringing better efficacy experience to Chinese patients.
Zhengrong years are all in the past, listen to the ophthalmology big coffee open the 8th anniversary of Langmu ®celebration prologue
Academician Fan Xianqun
"In the past eight years, Langmu ® has adhered to healthy and sustainable development, supported academic exchanges in ophthalmology, supported the development of ophthalmology, and made achievements in the training of young ophthalmology doctors." Academician Fan Xianqun said that it is expected that Kanghong Pharmaceutical will overcome difficulties, make new contributions, adhere to the clinical value-oriented, patient needs as the core, accelerate the research and development of innovative drugs and the construction of scientific research talents, benefit more patients with eye diseases, and make new and greater contributions to the development of China's ophthalmology cause and the construction of "Healthy China".
Professor Li Xiaoxin
"Langmu ® is the pride of China's ophthalmology community, before, the only thing that could produce anti-VEGF products in the world was the United States, when Kang Hong presented Langmu ® to the world, he gave Chinese a long ambition!"
Professor Li Xiaoxin said that since the beginning of the project, Langmu ® has received full support from the Ophthalmology Branch of the Chinese Medical Association, and since its approval in 2014, it has received full support from the Chinese ophthalmology community. In the past 8 years, Kang Hong has worked the basis of nAMD, has been approved DME, pmCNV indications, and now, Langmu ® has been approved RVO indications, China RVO treatment and disease management has since entered a new era of triple treatment upgrade.
"As a national pharmaceutical company, Kanghong Pharmaceutical has gone through a brilliant journey under the leadership of Chairman Ke Zunhong; Now, the baton has passed into the hands of President Ke Xiao. I believe that under his leadership, Kanghong will have more products on the market, and I hope that Kanghong Pharmaceutical will have more brilliant prospects! ”
Professor Yao Ke
"Langmu ® has achieved great results in the 8-year war against VEGF, bringing light and hope to more than 2 million Chinese patients." Professor Yao Ke said that in the new round of national medical insurance negotiations in 2021, Langmu ® has practiced the mission of "national innovation bears morality, and the national basic drug benefits the people", responds to the call of the state, and promises to take the lead in reducing prices in the Chinese market, supporting national medical insurance, and benefiting Chinese patients.
Professor Yao Ke said that as a national essential drug in the same therapeutic field, Langmu ® practices the basic drug responsibility of "prevention and treatment, safety and effectiveness, reasonable price, convenient use, basic guarantee, clinical first choice and grass-roots level can be equipped", and won the biological innovation drug of China Industrial Outline and the ophthalmic anti-VEGF products included in the Chinese Pharmacopoeia, laying the quality standard in this field. With the support and nurturing of the Chinese ophthalmology community, it has the international advanced level of similar products.
Professor Sun Xinghuai
In the past 8 years, Langmu ® has been approved for three major indications: nAMD, DME, pmCNV, and this year's RVO was successfully approved for listing, which is another good achievement for Langmu ®. So far, Langmu's ® indications have almost covered the main blinding eye diseases that need to be treated under the fundus, and congratulations to Langmu ® and Kanghong Pharmaceutical again!
In the past 8 years, China Ophthalmology has watched Langmu ® grow and grow step by step, and Langmu ® has broken the exclusive monopoly of foreign products on the Chinese market, prompting imported products to be forced to reduce prices in China many times, increasing the accessibility of Chinese patients, and giving Chinese patients more bright hope. At the same time, Kanghong Pharmaceutical continues to promote the development of ophthalmology in China and the scientific research and training of young and middle-aged doctors. In the field of ophthalmology, Langmu ® is currently the only product that is included in the national basic drug, included in the Chinese Pharmacopoeia, and has won the China Industry Award, which is the core product of Chinese ophthalmology and the benchmark of Chinese innovation. It is hoped that Kanghong Pharmaceutical will continue to innovate and persevere, make more contributions to Chinese ophthalmology, and benefit more patients.
Professor Wang Ningli
This time of year is an important moment for innovative ophthalmic drugs in China. Looking back 8 years ago, Langmu ® was just listed, and there was only one indication for nAMD; At present, Langmu ® has three major indications: nAMD, DME, pmCNV; This year, Langmu ® has achieved another good result, and another indication - RVO has been approved. Congratulations to Langmu ® again, congratulations to Kanghong Pharmaceutical!
Secretary-General Hu Guanghua
"Caring for China's ophthalmic medical staff is to guard the eyes of the Chinese people!" Secretary General Hu Guanghua introduced that since its launch in 2014, the "Lang Vision Mu Guangming" public welfare fund of the China Social Assistance Foundation has covered 30 provinces, municipalities and autonomous regions and 399 hospitals across the country. By the end of May 2022, a total of 83,044 drugs donated by Kang Hong, with a total value of 398 million yuan, had helped 65,273 patients with fundus diseases see the light again. At the same time, it also organized well-known experts at home and abroad to carry out free clinics in 14 border and poor areas of the country, helped 11,500 ophthalmologists organize 14 medical teaching activities, and improved the level of local ophthalmology diagnosis and treatment.
Secretary-General Hu Guanghua introduced that since the outbreak of the new crown epidemic, the China Social Assistance Foundation has once again joined hands with Kang Hong to initiate the establishment of the China Social Assistance Foundation "Lang Vision Mu Guangming" Medical Care Fund, which has carried out a series of activities such as publicity of eye diseases, science popularization and other activities, care for medical staff, academic training, and re-education activities. As of the end of May 2022, the Medical Care Fund has received more than 5 million yuan in donations, held more than 60 academic training or re-education activities, cared for hundreds of medical care and benefited 3,000 doctors.
"Whether it is on a special day or in daily life, the China Social Assistance Foundation's 'Lang Vision Mu Guangming' medical care project will accompany Chinese ophthalmologists all the way forward and promote the development of China's ophthalmology cause!" Secretary General Hu Guanghua said.
Ke Xiao, President of Kanghong Pharmaceutical
President Ke Xiao said in his speech that since the listing of the world's latest generation of anti-VEGF fusion protein and the national original first-class biological new drug Langmu ® in 2014, under the trust and support of experts and scholars in the field of ophthalmology in the mainland, it has braved thorns and thorns all the way, riding the wind and waves, has accumulated more than 1.8 million sales, carried out more than 80 original research of various types, and published more than 1500 related papers in authoritative journals at home and abroad, including more than 240 SCI articles, which has won the trust of the majority of doctors and patients, known as " The Light of Innovation in China's Biopharmaceutical Sector".
"This is not only recognition and honor, but also makes us feel the mission and responsibility of being a national pharmaceutical company." President Ke Xiao said that the world today is in a century of unprecedented changes, at this critical moment, Kang Hongren is well aware of the mission and responsibility as a Chinese pharmaceutical company, and will adhere to the "innovation-driven development" corporate strategy, with greater courage and determination, in the core treatment areas including ophthalmology to accelerate the layout, to provide the world with more and better "China solutions". Kanghong will always adhere to the business philosophy of "innovation as the core, quality as life", and grow together with Chinese ophthalmology.
Yin Jinqun, director and vice president of Kanghong Pharmaceutical
"Taking the road of independent research and development of innovative drugs is a difficult and tortuous road, but only by adhering to national innovation can we create Chinese proud drugs." Yin Jinqun stressed that Kanghong Pharmaceutical's return and gratitude to China's ophthalmology will also be reflected in its insistence on continuous innovation.
At the beginning of the year, under the stalemate of the reluctance to reduce the price of imported products in the same field, Langmu ® was included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" at the most beautiful medical insurance price of 3452.80 yuan per cigarette, benefiting more Chinese ophthalmic patients, reflecting Kanghong Pharmaceutical's determination to "develop for the people and innovate for the people". Yin Jinqun introduced that in addition to Langmu ®, Kanghong Pharmaceutical is also committed to innovative gene drugs, representing China to continue to compete with the world's top products.
In the future, Kanghong Pharmaceutical will build more academic research platforms to assist Chinese ophthalmologists to exert their fists and feet on the international stage and shine fever; Work together with the majority of ophthalmologists in China to take the weapon into the hands of Chinese ophthalmologists themselves and bring light to Chinese patients; Work with all parties to help realize the mainland's leap from running to running and leading in the field of ophthalmology, meet the brilliant future of Chinese ophthalmology together, and embrace the sea of stars of innovation!
Ophthalmologists at home and abroad gathered at the grand event to celebrate the 8th anniversary of Langmu ®
In order to celebrate the "clear love, only for China" eight years of anti-VEGF war and innovation light - the 8th anniversary of The listing of Langmu ®, ophthalmology experts came with heavy topics to celebrate the highlight moment of ophthalmology with academic gifts!
Professor Yan Hua: Will be the top of the top - research progress in the pharmacoeconomics of anti-VEGF treatment in China
Professor Yan Hua introduced a study on the effect of Campercept versus monoclonal antibody anti-VEGF drugs in the treatment of AMD, DME and PM, which was based on population cohort studies and Markov models. This study is the first pharmacoeconomic evaluation based on real-world scenario analysis and comparing the clinical effects and cost-effectiveness of Cambachip and rizumab in the treatment of AMD, DME and PM. AmD, DME, and PM have a heavy global burden of disease, and this study can provide important insights for scientific decision-making on therapeutic drugs for AMD, DME, and PM in low- and middle-income countries. The study found that conbascipline was more cost-effective in treating AMD, DME and PM than monoclonal antibody anti-VEGF drugs.
Professor Xu Xun: The Era of Precision: An Exploration of the Direction of Ophthalmology Diagnosis and Treatment
Professor Xu Xun shared a national key research and development program precision medicine project, which is to establish a database of large samples of real-world Compaxipu anti-VEGF treatment, conduct clinical treatment phenotypic difference analysis, and then achieve precision medicine. The six research objectives of the project were elaborated: the establishment of a multi-center diagnosis and treatment registration system for fundus pathogen research and new drugs in line with international norms; Formed a clinical efficacy evaluation platform for neonatal neovascular diseases under the macula that conforms to international norms; Established a standard reading process (SOP) for neodymanovascular disease under the macula; Establishment of a biobank of submacular neovascular diseases; Based on omics big data, the core biomarkers oriented to the precise application of drugs were screened; A data analysis process for multiple groups of student markers (molecular feature profiles) oriented to the precise application of drugs for eye diseases was established.
Professor Chen Youxin: When sitting and watching the clouds rise: from the START study to see the progress of PCV diagnosis and treatment in China
The START study was an open-ended, non-randomized, multicenter, prospective, observational study that evaluated the treatment economically to observe the true and prognosis of the use of combercept in pcv patients in mainland China, selected PCV-China as a long-term follow-up cohort, and enrolled 499 PCV patients in 28 hospitals in different parts of the continent. The RESULTS OF THE START STUDY SHOWED THAT COMBACHIP MONOTHERAPY FOR PCV WAS EFFECTIVE AND SAFE; 81% of patients achieved a significant improvement in vision, with an average BCVA improvement of 4.8 letters from baseline (average 3.3 stitches); for patients with baseline vision equal to less than 39 letters, the improvement in vision was very pronounced. In addition, Professor Chen Youxin pointed out that the use of anti-VEGF drugs to treat PCV patients, adequate anti-VEGF treatment can improve the vision of PCV patients and remain stable, it is recommended to complete the loading phase of 3 consecutive drugs; Under the influence of the epidemic, adequate visits (at least 4 visits per year are recommended) can bring better vision assurance to PCV patients.
Professor Wei Wenbin: RVO indications have been approved, and the treatment has entered a new era of triple upgrading
Retinal vein occlusion (RVO) is a blinding eye disease that is particularly common in the elderly population. Retinal vein occlusion is most common with branch vein occlusion (BRVO), followed by central retinal vein occlusion (CRVO). One-third of patients in the former have macular edema, while in the latter 70% have macular edema. Professor Wei Wenbin, the main investigator of the RVO PHASE III study BRAVE study and the CRANE study, introduced that in the BRAVE study, BRVO patients used combexip every month, and after 3 months of injection, the average optimal corrected vision improvement was 15.3 letters, and one year later, the average optimal corrected vision improvement was 15.3 letters; in the CRAVE study, CRVO patients used Combersip every month, and after 3 months of injection, the average optimal corrected vision improvement was 11.7 letters, and one year later, the average optimal corrected vision improvement was 11.7 letters, and one year later, the improvement was 14.4 letters. This data gives clinicians and patients strong confidence and hope! In a way, this result is an exciting news for the entire pharmaceutical industry, reflecting the quality and efficacy of China's innovative products.
In addition, Academician Fan Xianqun, Professor Lin Xiaofeng, Professor Jin Zibing, Professor Sun Xiaodong, Professor Song Yanping, Professor Chi Wei, Professor Zhang Meixia, Professor Zhang Hong, Professor Li Tao, Professor Wang Chaoyang, Professor Lu Fang, Professor Qi Yue, Professor Peter K. Kaiser, Professor Jeffrey S. Heier brought wonderful lectures, including the latest progress in the treatment of fundus diseases, the clinical challenges of RVO diagnosis and treatment, the exploration of ophthalmic diagnosis and treatment in the precision era, the interpretation of RVO Phase III clinical research reports, The academic frontiers of real-world exploration and research, how scientific and technological innovation and transformation can promote the development of precision medicine, etc., are full of dry goods, which has triggered in-depth thinking and discussion among the participants.
Subsequently, Professor Qu Jia, Professor Xu Gezhi, Professor Liang Xiaoling, Professor Xu Xun, Professor Lin Xiaofeng, Professor Fang Xiaoyun, Professor Li Wensheng, Professor Wang Min, Professor Zhang Liang, Professor Chen Youxin, Professor Lu Fang, Professor Li Xiaoxin, Professor Ma Zhizhong, Professor Jin Zibing, Professor Lu Hai, Professor Xu Zhuping, Professor Lü Lin, Professor Song Yanping, Professor Chi Wei, Professor Liu Kun, Professor Shen Lijun, Professor Chen Zhiqing, Professor Cheng Hao, Professor Sun Xufang, Professor Yu Suqin, Professor Yao Jin, Professor Lü Fan, Professor Chang Qing, Professor Zhang Wenfang, Professor Wei Wenbin, Professor Li Xiaorong, Professor Zhang Meixia, Professor Ma Xiang, Professor Dai Hong, Professor Peter K. Kaiser, Professor Jeffrey S. Heier put forward hot and difficult issues in the conference, and the experts expressed their opinions and exchanged views, and the collision of ideas triggered more academic exchanges and pushed the conference to a climax.
The journey is long, only struggle! Langmu ® will work with China Ophthalmology to create brilliant again!
With independent research and development and production of drugs, related to the strategic security of the country, as a representative of national enterprises, Kanghong Pharmaceutical has always insisted on continuous innovation, walking in the forefront of academics, and tackled the problem of "stuck neck" of anti-VEGF drugs, which has great value. Professor Yan Hua and Professor Lin Xiaofeng said that they once again congratulated Langmu ®on its 8th anniversary and congratulations on the approval of RVO indications! It is believed that Kanghong Pharmaceutical will continue to innovate and develop in the field of ophthalmology, provide more "weapons" for ophthalmic medical staff, better benefit Chinese eye patients, and make new contributions to Chinese ophthalmology! China Ophthalmology will continue to walk hand in hand with Kanghong Pharmaceutical and pursue dreams together!